Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Schmidinger

Showing results (31-40 of 112) with videos related to

Pageof 12
Sort By:
Future Oncology (London, England)|December 16, 2021
CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinomaLaurence Albiges, Manuela Schmidinger, Naila Taguieva-Pioger, et al.
Current Opinion in Urology|March 20, 2021
What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literatureKeiichiro Mori, Manuela Schmidinger, Fahad Quhal, et al.
European Urology Focus|February 12, 2023
Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell CarcinomaTakafumi Yanagisawa, Manuela Schmidinger, Tatsushi Kawada, et al.
Wiener Medizinische Wochenschrift (1946)|January 1, 2003
[Aerobic physical training in a breast cancer patient with inflammatory recurrence]R Crevenna, Veronika Fialka-Moser, M Y Keilani, et al.
Anti-Cancer Drugs|March 21, 2013
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to boneEduard Vrdoljak, Brian Rini, Manuela Schmidinger, et al.
BMC Cancer|August 18, 2016
Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevanceCaroline Razafinjatovo, Svenja Bihr, Axel Mischo, et al.
Cancers|April 3, 2019
Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?Renate Pichler, Eva Compérat, Tobias Klatte, et al.
Future Oncology (London, England)|December 22, 2017
Individualized dosing with axitinib: rationale and practical guidanceManuela Schmidinger, Romano Danesi, Robert Jones, et al.
Targeted Oncology|May 6, 2025
Efficacy of First-Line Treatments for Advanced Renal Cell Carcinoma: A Bayesian Network Meta-analysis of Objective Response, Progression-Free Survival, and Overall SurvivalManuela Schmidinger, Pratik P Rane, Kevin Yan, et al.
Acta Oncologica (Stockholm, Sweden)|July 9, 2011
Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinomaWolfgang Lamm, Ursula Maria Vogl, Marija Bojic, et al.
Pageof 12

Showing results (31-40 of 112) with videos related to

Sort By:
Pageof 12
Future Oncology (London, England)|December 16, 2021
CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinomaLaurence Albiges, Manuela Schmidinger, Naila Taguieva-Pioger, et al.
Current Opinion in Urology|March 20, 2021
What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literatureKeiichiro Mori, Manuela Schmidinger, Fahad Quhal, et al.
European Urology Focus|February 12, 2023
Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell CarcinomaTakafumi Yanagisawa, Manuela Schmidinger, Tatsushi Kawada, et al.
Wiener Medizinische Wochenschrift (1946)|January 1, 2003
[Aerobic physical training in a breast cancer patient with inflammatory recurrence]R Crevenna, Veronika Fialka-Moser, M Y Keilani, et al.
Anti-Cancer Drugs|March 21, 2013
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to boneEduard Vrdoljak, Brian Rini, Manuela Schmidinger, et al.
BMC Cancer|August 18, 2016
Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevanceCaroline Razafinjatovo, Svenja Bihr, Axel Mischo, et al.
Cancers|April 3, 2019
Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?Renate Pichler, Eva Compérat, Tobias Klatte, et al.
Future Oncology (London, England)|December 22, 2017
Individualized dosing with axitinib: rationale and practical guidanceManuela Schmidinger, Romano Danesi, Robert Jones, et al.
Targeted Oncology|May 6, 2025
Efficacy of First-Line Treatments for Advanced Renal Cell Carcinoma: A Bayesian Network Meta-analysis of Objective Response, Progression-Free Survival, and Overall SurvivalManuela Schmidinger, Pratik P Rane, Kevin Yan, et al.
Acta Oncologica (Stockholm, Sweden)|July 9, 2011
Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinomaWolfgang Lamm, Ursula Maria Vogl, Marija Bojic, et al.
Pageof 12